Genocea sets share number for follow-on
Infectious disease company Genocea Biosciences Inc. (NASDAQ:GNCA) said it plans to sell 3.4 million shares in a follow-on underwritten by Citigroup; Cowen; Stifel; and Needham. Genocea proposed to raise up to $60 million in the offering on July 3. If sold at the company's close of $14.87 on Friday, before Genocea set the share figure, the company would raise $50.6 million.
Genocea's GEN-003 is in a Phase I/IIa trial to treat herpes simplex virus type 2 (HSV-2) infection, with Phase II testing slated to start this year. GEN-003 is a T cell vaccine consisting of the infected cell polypeptide 4 (ICP4) and gD2 antigens from HSV-2 combined with the saponin-derivative adjuvant Matrix M. This quarter, the company plans to start a Phase IIa trial of GEN-004, a T cell vaccine against Streptococcus pneumoniae. ...